+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins



New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins



Expert Review of Neurotherapeutics 7(12): 1731-1750



The authors review current literature on hallucinations in Parkinson's disease (PD). Recent neuropathological studies showed that hallucinations occur in synucleinopathies and are a significant predictor of Lewy Body depositions. Therefore, hallucinations are a hallmark of PD and of dementia with Lewy Bodies. Visual hallucinations are mostly complex and kinematic; preserved or disturbed insight on the nature of hallucinations is a major prognostic factor, although eventually all hallucinators will present with reduced insight. Current theories on the origin of hallucinations point to visual dysfunction, dream overflow and cognitive impairment, yet objection can be raised on each one of the putative models of hallucinations. Understanding of the origin of hallucinations is required in order to develop treatments: all treatment evaluations were focused in general on psychosis, and only clozapine obtained positive evidence-based ratings on efficacy. However, it is likely that cholinesterase inhibitors, antipsychotics and anti-5-hydroxytryptamine(3) agents and drugs acting on sleep regulation will have different and perhaps opposite effects on different types of hallucinations, whether they are accompanied by disturbed insight, sleep disorders or other psychotic features. Further studies will try to separate phenomenology and responses to treatment and will investigate the relevance of concomitant sleep disorders and abnormality of frontoparietal networks involved in the attention process.

(PDF emailed within 0-6 h: $19.90)

Accession: 054600258

Download citation: RISBibTeXText

PMID: 18052766

DOI: 10.1586/14737175.7.12.1731


Related references

Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 83(10): 1019-1021, 2012

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123: 733-745, 2000

Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745. American Journal of Ophthalmology 130(2): 261-262, 2000

Visual hallucinations in Parkinson's disease: clues to separate origins. Journal of the Neurological Sciences 248(1-2): 143-150, 2006

Visual hallucinations in Parkinson's disease: their nature, frequency, and origins. Journal of Neurology, Neurosurgery, and Psychiatry 70(6): 719-720, 2001

Study of associated clinical variables and phenomenology of hallucinations in Parkinson's. Neurologia 21(1): 12-18, 2006

From phenomenology to neurophysiological understanding of hallucinations in children and adolescents. Schizophrenia Bulletin 40 Suppl 4: S221-S232, 2015

Interdisciplinary approaches to the phenomenology of auditory verbal hallucinations. Schizophrenia Bulletin 40 Suppl 4: S246-S254, 2015

Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. Cns Spectrums 13(3 Suppl 4): 18-25, 2008

Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease. Annals of General Psychiatry 5: 12-12, 2006

New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2. Biochemical Journal 424(1): E1-E3, 2009

Computational approaches for understanding the diagnosis and treatment of Parkinson's disease. Iet Systems Biology 9(6): 226-233, 2016

LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. Febs Journal 276(22): 6445-6454, 2010

A comparison of montreal cognitive assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease. Clinical Neurology and Neurosurgery 130(): 98-100, 2015

The Relevance of Explanatory First-Person Approaches (EFPA) for Understanding Psychopathological Phenomena. The Role of Phenomenology. Frontiers in Psychology 9: 694-694, 2018